VaxThera
VaxThera is a Colombian biotechnology company founded in 2021 that develops and manufactures human and veterinary vaccines using mRNA and MVA viral-vector platforms, and operates a 100+ million dose fill-and-finish plant in Rionegro. It serves Colombian government health programs, insurance partners (Seguros SURA), and regional LATAM markets.
- Company typePrivate
- Founded2021
- HeadquartersRionegro, Colombia
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What VaxThera does
VaxThera is a Colombian biotechnology company founded in 2021 that designs, develops, and manufactures human and veterinary vaccines, with a stated mission to restore domestic vaccine production for Colombia after more than 20 years of import dependence. The company operates two technology platforms — an mRNA platform anchored on Quantoom Technologies' Ntensify™ automated cell-free production system, and an MVA viral vector platform — and offers fill-and-finish contract manufacturing services for third-party vaccine producers. Its pipeline includes the USPTO-patented UniVax universal COVID-19 vaccine (mosaic antigen design), vaccines in development against Zika, Chikungunya, and Yellow Fever, and a Personalized Prevention Program (PPP) delivered through insurance partners that addresses adult vaccination gaps outside the government-funded Expanded Immunization Program (PAI). The most material commercial initiative to date is the September 2025 launch of a region-leading HPV prevention program (Gardasil 9®) with parent company Seguros SURA, targeting more than 50,000 doses across six Colombian cities.
The company is organized across three legal entities: VaxThera S.A.S. in Medellín (commercial and R&D headquarters), VaxThera Zona Franca S.A.S. in Rionegro (the 35,000 m² LEED Gold-certified manufacturing plant, Phase 1 capacity of 100+ million doses annually, scaling to 200–300 million in Phase 2), and VaxThera LLC in Madison, Wisconsin (R&D and scientific collaboration with the University of Wisconsin-Madison). The R&D footprint includes an 820 m² research laboratory equipped with mRNA and viral-vector capabilities.
VaxThera is a wholly-owned subsidiary of Seguros SURA Colombia (part of Grupo SURA), which has committed approximately $100 million USD across plant construction, R&D capabilities, and talent acquisition. Revenue is generated through institutional channels: B2B sales to the Colombian government (PAI), B2B2C partnerships with insurance providers (SURA), contract fill-and-finish services for third-party vaccine producers, and technology transfer/licensing agreements with international partners including Gennova (India), Instituto Butantan (Brazil), and Univercells (Belgium). GMP certification processes are concurrently underway with INVIMA, COFEPRIS, FDA, and EMA, signaling an explicit export orientation. Current headcount of 11–50 is projected to scale to 500+ within five years as commercial production comes online.
VaxThera firmographics
Firmographics- Name
- VaxThera
- Legal name
- VaxThera S.A.S.
- Website
- https://vaxthera.com
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- VaxThera is a Colombian biotechnology company founded in 2021 that develops and manufactures human and veterinary vaccines using mRNA and MVA viral-vector platforms, and operates a 100+ million dose fill-and-finish plant in Rionegro. It serves Colombian government health programs, insurance partners (Seguros SURA), and regional LATAM markets.
- Ownership category
- akta.pro rank
VaxThera industry classification
Industry- Product category
- Vaccine Manufacturing and Biologics
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Vaccine Technology Platforms (Live, Inactivated, Subunit, Vector, mRNA/DNA) (HLAMAKAH)
- akta.pro secondary industries
- Clinical Development & Regulatory for Vaccines (trials, pharmacovigilance, lot release) (HLAAAEAK), Travel & Tropical Disease Vaccines (HLAIAEAE), Immunization & Vaccine Delivery Programs (BPADAIAB)
Keywords
Where VaxThera is headquartered
LocationHeadquarters
- HQ city
- Rionegro
- HQ country
- Colombia
- HQ region
- Latin America
Offices4 records
Markets served
VaxThera business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales, Supply Chain
Revenue model
- Vaccine Manufacturing and Sales: VaxThera manufactures and sells vaccines domestically and regionally, including products for the Expanded Immunization Program (PAI) such as HPV, Pentavalent, Pneumococcal, Influenza, Polio, and Rotavirus vaccines. Production capacity exceeds 100 million annual doses.
- Personalized Prevention Programs (PPP): B2B2C vaccination programs offered in partnership with insurance companies like SURA, providing preventive healthcare services to policyholders. Programs target diseases like HPV and influenza.
- Technology Transfer and Licensing: Co-development and technology transfer partnerships with international pharmaceutical companies for vaccine production in Latin America, including agreements with companies from India, USA, Europe, and Latin America.
- Contract Manufacturing: Fill-and-finish services for third-party vaccine products, leveraging state-of-the-art facilities and GMP compliance.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Multi-year contract | Personalized Prevention Program (PPP) - Free vaccination for SURA policyholders |
Go-to-market motion2 records
Distribution channels4 records
Marketing channels7 records
VaxThera product offering
Product offeringCore offering
VaxThera is a Colombian biotechnology company that researches, develops, and manufactures human and veterinary vaccines and biological products using mRNA and MVA viral vector technology platforms. It operates a 35,000 m² LEED Gold-certified manufacturing plant in Rionegro, Antioquia with capacity for more than 100 million doses per year, providing fill-and-finish contract manufacturing services and producing vaccines for the Expanded Immunization Program (PAI), HPV, Pentavalent, Pneumococcal, Influenza, Polio, and Rotavirus. The company also delivers Personalized Prevention Programs (PPP) — including the largest HPV prevention program in Latin America in partnership with Seguros SURA — targeting adult populations aged 18-59 outside the standard immunization schedule.
Product overview
VaxThera is a Colombian biotechnology company developing a diversified portfolio of human and veterinary vaccines alongside contract manufacturing services. Core products include UniVax (universal COVID-19 vaccine) and vaccines in pipeline targeting Zika, Chikungunya, and Yellow Fever. The company operates two technology platforms (mRNA and viral vector) and offers fill-and-finish manufacturing services with capacity of 100 million doses annually. Healthcare services include Personalized Prevention Programs (PPP) for adult vaccination and large-scale HPV prevention programs. VaxThera S.A.S. (Medellín) handles research and commercialization, VaxThera Zona Franca S.A.S. (Rionegro) manages production, and VaxThera LLC (Wisconsin, USA) focuses on R&D.
Differentiator
Problem solved
Functional benefit
Products and services
- Fill-and-Finish Manufacturing Services
Quantifiable outcome
- 100 million+ doses annual production capacity
- +3 more outcomes
Companies that use VaxThera
Customer profileNamed customers4 records
Segments4 records
Ideal customer profiles4 records
VaxThera technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
VaxThera partnerships and signals
Strategic signalPartnerships
Ten partnerships are on record, tiered core and flagship.
- Ministerio de Salud y Protección Social de ColombiacoreConvenio Marco Especial de Cooperación Científica y Tecnológica between Minsalud, INS, and VaxThera to strengthen local capabilities in biological research, development, and production for health sovereignty. Includes researcher exchange, joint project formulation, technology transfer, and identification of priority biologics for local production.
- Instituto Nacional de Salud (INS)coreStrategic partnership for cooperation in scientific, technical, and technological development of biologics and health technologies. Aims to strengthen local capacity for public health emergency response and establish long-term health sovereignty for Colombia.
- Univercells (Belgium)flagshipCollaboration agreement for vaccine development using viral vector and mRNA platforms with state-of-the-art automated equipment. This partnership represents VaxThera's route to production and is part of the company's strategic manufacturing capabilities.
- Instituto Butantan (Brazil)coreMemorandum of understanding for bilateral technology transfer for vaccine production. Butantan is the largest vaccine and serum producer in Latin America, responsible for most immunobiological production in Brazil including 100% of influenza vaccines for Brazil's National Immunization Campaign.
- Universidad Nacional de ColombiacoreAcademic partnership for vaccine research and development, including joint work on Zika, Chikungunya, and Yellow Fever vaccines under co-financing from Colombia's Ministry of Science, Technology and Innovation.
- Quantoom Technologies (Ntensify™ System)flagshipAcquisition of unique Ntensify™ system equipment in Colombia and Latin America for automated, cell-free mRNA vaccine production technology. This equipment enables more efficient, higher quality, and safer vaccine production.
- USDA - United States Department of AgriculturecoreFunding partnership for veterinary COVID-19 vaccine development with University of Wisconsin-Madison to evaluate UniVax for limiting virus transmission across multiple animal species and reducing zoonotic transmission risk to humans.
- Gennova Biopharmaceuticals (India)coreLong-term alliance for mRNA and other biological products technology. Initial phase includes commercialization of Gennova products in Colombia and Latin America, with joint efforts to strengthen technology experience and scientific resource management for local vaccine and biologic production capabilities.
- Universidad de Wisconsin-Madison (USA)coreFounding scientific partner providing expertise in vaccine development. Founder Dr. Jorge Emilio Osorio serves as professor at the university, and the company maintains R&D operations in Wisconsin. Collaborative research on emerging infectious diseases including COVID-19, Zika, Chikungunya, and Yellow Fever.
- Universidad Nacional de ColombiacoreAcademic ally for scientific research, talent development, and vaccine development programs.
Scale indicators10 records
Recent moves12 records
Expansion highlights7 records
VaxThera competitors and assessment
Company assessmentDirect peers
- Instituto Butantan: Latin America's largest vaccine and serum producer (100% of Brazil's influenza PNI supply) and a signed VaxThera technology-transfer partner. Comparable in mandate (public-sector vaccine sovereignty), scale of domestic production, and pipeline scope across tropical diseases.
- Gennova Biopharmaceuticals: Indian mRNA technology partner with a long-term alliance for biological products commercialization in LATAM. Comparable as an emerging-market biologics manufacturer developing mRNA and other biologics with technology-transfer-driven growth.
- Bharat Biotech: India-headquartered vaccine developer with a diversified human vaccine portfolio including viral and emerging-disease candidates (rotavirus, chikungunya). Comparable in multi-platform vaccine strategy, emerging-market focus, and contract manufacturing for governments.
Emerging players
- Biological E: Indian vaccine manufacturer with large-scale fill-finish capacity and PAI-relevant pediatric vaccines (Pentavalent, Pneumococcal). Comparable in targeting emerging-market immunization tenders at scale.
- Sinovac Biotech: China-based vaccine producer with broad pediatric portfolio (including COVID-19 and influenza) and significant emerging-market exports. Comparable in operating model of government-aligned regional vaccine production.
- CureVac: Earlier-stage mRNA company with a platform spanning prophylactic vaccines and oncology. Comparable as an mRNA platform developer commercializing through technology partnerships rather than solely direct sales.
Broad incumbents
- Moderna: Global mRNA platform incumbent with deep R&D pipeline and large commercial scale. Relevant as the benchmark for the mRNA platform VaxThera is deploying via Quantoom's Ntensify system.
- Sanofi Pasteur: Global vaccine incumbent with broad pediatric and adult portfolio. Comparable as a competing supplier to LATAM immunization programs and a reference point for the PAI antigens VaxThera plans to produce domestically.
- GSK Vaccines: Global vaccine major with extensive pediatric and adult immunization portfolio. Competes for the same PAHO/WHO procurement contracts that VaxThera would target regionally.
Others
- Quantoom Biosciences: Belgian technology provider of the Ntensify cell-free mRNA production system that VaxThera has deployed. Comparable as an enabler/ecosystem participant supporting VaxThera's manufacturing platform.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
VaxThera social profiles
Digital presenceVaxThera compliance and trust
Trust signalCompliance5 records
VaxThera financial estimates
Financial estimateRevenue estimate
Valuation estimate
VaxThera leadership team
Management profileNumber of profiles
Profiles9 records
VaxThera subsidiaries and ownership
Company hierarchySubsidiaries2 records
VaxThera funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
VaxThera M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about VaxThera
What does VaxThera do?
VaxThera is a Colombian biotechnology company that researches, develops, and manufactures human and veterinary vaccines and biological products using mRNA and MVA viral vector technology platforms. It operates a 35,000 m² LEED Gold-certified manufacturing plant in Rionegro, Antioquia with capacity for more than 100 million doses per year, providing fill-and-finish contract manufacturing services and producing vaccines for the Expanded Immunization Program (PAI), HPV, Pentavalent, Pneumococcal, Influenza, Polio, and Rotavirus. The company also delivers Personalized Prevention Programs (PPP) — including the largest HPV prevention program in Latin America in partnership with Seguros SURA — targeting adult populations aged 18-59 outside the standard immunization schedule.
Is VaxThera a public or private company?
VaxThera is a private company. It is classified as corporate owned and is currently operating.
When was VaxThera founded?
VaxThera was founded in 2021. It employs 11 to 50 people.
Where is VaxThera based?
VaxThera is headquartered in Rionegro, Colombia, in the Latin America region.
How does VaxThera make money?
Four revenue lines are on record. Vaccine Manufacturing and Sales are the primary driver. The others are personalized Prevention Programs (PPP), technology Transfer and Licensing and contract Manufacturing.
Who are VaxThera's main competitors?
Direct peers on record are Instituto Butantan, Gennova Biopharmaceuticals and Bharat Biotech. Emerging players are Biological E, Sinovac Biotech and CureVac. Broad incumbents are Moderna, Sanofi Pasteur and GSK Vaccines. Quantoom Biosciences is listed as an others.
Does VaxThera have an API?
No public API is recorded for VaxThera.
What industry is VaxThera in?
VaxThera's product category is Vaccine Manufacturing and Biologics. Its primary akta.pro industry code is HLAMAKAH, Vaccine Technology Platforms (Live, Inactivated, Subunit, Vector, mRNA/DNA), with a secondary code of HLAAAEAK, Clinical Development & Regulatory for Vaccines (trials, pharmacovigilance, lot release). Its NAICS code is 325414 and its SIC code is 2836.